🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

RecruitingPhase 2, Phase 3Ages 50 Years - anyAllEyeBiotech Ltd.
NCT07440225 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
The main inclusion criteria include but are not limited to the following: * Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye) * The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment The main exclusion criteria include but are not limited to the following * Has uncontrolled blood pressure at screening * History of any prior macular laser photocoagulation in the study eye * History of uveitis in either eye * History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study * Has uncontrolled glaucoma in the study eye * Active retinal disease other than the condition under investigation in the study eye * Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye
💊

What it tests

  • Tiespectus
  • Aflibercept
📍

Where

132 sites
Research Network Arizona / Retina Macula Institute of Arizona
Scottsdale, United States
Retina Center of Arkansas
Fayetteville, United States
Retina Partners of Northwest Arkansas, PLLC
Springdale, United States
Global Research Management, Inc.
Glendale, United States
Retinal Consultants Medical Group (Site 024)
Modesto, United States
Azul Vision / California Eye Specialists Medical Group, Inc.
Pasadena, United States
Retina Consultants of Southern California (Site 043)
Redlands, United States
Retinal Consultants Medical Group (Site 020)
Sacramento, United States

…and 124 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy